Hakimeh Ebrahimi-Nik

Hakimeh Ebrahimi-Nik studies how tumors evade the immune system and how this can be reversed to improve cancer immunotherapy. Their work examines specific molecular targets, such as protein tyrosine phosphatases (enzymes that regulate immune cell signaling) and antigen-processing pathways, and uses tools like CRISPR gene-editing screens and mass spectrometry to identify tumor-specific markers (neoepitopes) that immune cells can recognize. Much of this research is preclinical, using mouse cancer models to test small-molecule drugs and immune checkpoint inhibitors that boost T-cell and NK-cell activity against tumors.

Publication output has been relatively steady at around 2-3 papers per year over the last decade, with a slight uptick in 2022 and continued consistent output through 2025-2026.

Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026